Professor Constantine (Con) Tam is Head of the Lymphoma Service at Alfred Health and Central Clinical School.

Con received his M.B.B.S.(Hons) and M.D. degrees from the University of Melbourne. After dual training in Haematology and Haematopathology, Con completed his Leukemia Fellowship at MD Anderson Cancer Centre in Houston, Texas. Prior to moving to the Alfred, Con served as Disease Group Lead for Low Grade Lymphoma and CLL at Peter MacCallum Cancer Centre & Royal Melbourne Hospital for over 10 years. He is also past Director of Haematology at St. Vincent's Hospital.

Con is passionate about developing new treatments for blood cancers. He is the global lead for the BTK inhibitor zanubrutinib, and oversaw its development from the first-in-human dosing (in Melbourne) to successful international licensing studies worldwide. Con designed and performed the first global study to combine ibrutinib and venetoclax, publishing the results in the New England Journal of Medicine 5 years after inception. In 2015, he became the Australian lead for the pivotal study of Tisagenlecleucel in diffuse large B-cell lymphoma, leading to public funding for CAR T-cells as standard treatment in Australia.

The publication record for Con includes 240 peer-reviewed papers in New England Journal of Medicine, Lancet, Journal of Clinical Oncology, Blood and other top-tier journals. His work has been cited >17,000 times in the literature. Con is the current Lymphoma Editor for Blood Advances.